Related by context. Frequent words. (Click for all words.) 84 evaluable patients 68 mg BID 68 free survival PFS 68 Median survival 67 FOLFOX 66 median PFS 66 n = 65 Secondary endpoints include 65 tumor shrinkage 65 randomized #:# 64 metastatic renal cell carcinoma 64 mg/m2 63 Secondary endpoints included 62 dose limiting toxicities 62 ≥ 62 liver metastases 62 primary efficacy endpoint 62 hematologic 62 composite endpoint 61 secondary endpoint 61 febrile neutropenia 61 randomized 61 treatment emergent adverse 61 pharmacodynamic 61 mg dose 61 primary endpoint 61 unresectable 61 events AEs 61 HCV genotype 1 61 chemoradiation 60 secondary endpoints 60 monotherapy 60 plus ribavirin 60 peginterferon 60 imatinib 60 tumor regression 60 infliximab 60 vandetanib 59 NSCLC 59 HCV RNA 59 thrombocytopenia 59 gefitinib 59 dasatinib 59 resected 59 statistically significant improvement 59 sunitinib 59 histologic 59 mitoxantrone 59 tumor recurrence 59 LVEF 58 primary endpoints 58 docetaxel 58 adalimumab 58 demonstrated statistically significant 58 HGS ETR1 58 gemcitabine 58 rituximab 58 P = .# 58 pegylated interferon 58 IMGN# 58 dose escalation 58 postoperatively 58 mg d 58 SAEs 58 efficacy endpoints 58 etanercept 58 carboplatin 58 clinically meaningful 57 log# 57 ACR# [002] 57 castration resistant prostate cancer 57 limiting toxicity 57 bortezomib 57 p = #.# [004] 57 randomization 57 adjuvant therapy 57 adjuvant chemotherapy 57 Phase 2b study 57 mg m 57 mg kg 57 HRPC 57 placebo 57 p = #.# [002] 57 ZYBRESTAT 57 trastuzumab 56 Phase 1b 56 Phase 2a trial 56 seroconversion 56 fludarabine 56 discontinuations 56 fluorouracil 56 copies mL 56 confidence interval CI 56 placebo p = 56 % CI #.#-#.# [006] 56 topotecan 56 resistant ovarian cancer 55 retreatment 55 ACTEMRA 55 dexamethasone 55 tolerated dose MTD